Kura Oncology, Inc.

KURA

$1.60B

Small Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO192 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jun 12, 2026

17w

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

3 upcoming, 1 past

🎯PDUFANext

FDA PDUFA Date tipifarnib (priority)

6/12/2026

For relapsed or refractory HRAS-mutant head and neck squamous cell carcinoma (HNSCC). NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date Tipifarnib (priority)

7/1/2026

For relapsed or refractory HRAS-mutant head and neck squamous cell carcinoma (HNSCC). NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date ziftomenib (priority)

10/22/2026

For acute myeloid leukemia (AML). NDA filing. Extracted from SEC filing: 8-K

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Ziftomenib

Phase 3

Acute Myeloid Leukemia (AML)

Tipifarnib

Phase 2

HNSCC

Midazolam

Phase 2

Advanced Malignant Neoplasm

Drug Name	Phase	Indication	Designations
Ziftomenib	Phase 3	Acute Myeloid Leukemia (AML)	-
Tipifarnib	Phase 2	HNSCC	-
Midazolam	Phase 2	Advanced Malignant Neoplasm	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

KURA News